The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Desipramine in the treatment of adolescents with attention deficit disorder

Published Online:https://doi.org/10.1176/ajp.141.7.906

Twelve adolescents with attention deficit disorder were treated with desipramine in an open trial to assess its efficacy and safety. Eleven patients improved within 1 month, and improvement was sustained for 6- 12 months without significant adverse effects in nine patients.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.